Koninklijke Philips N.V., a leading global manufacturer of health technology products, has agreed to pay over $62 million in settlement charges brought by the US Securities and Exchange Commission (SEC). The Dutch company has been accused of engaging in improper conduct and bidding practices in China between 2014 and 2019, which involved influencing foreign officials to increase the likelihood of their products being chosen in public tenders.
This item is available in full to subscribers.
To continue reading, you will need to either log in to your subscriber account, below, or purchase a new subscription.
If you are a current subscriber, and had an account on our previous site, you already have an account. If you have not yet logged into our new site, click here to reset your password.
Otherwise, click here to view your options for subscribing.
Please log in to continue |